Healthcare / BiotechnologyStockholm
$2.79
-0.10 (-3.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-21.6M · quality 54.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$139M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-74.5%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-17.4M · FCF $-21.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-17.4M | $-17.4M | $-16.1M | $-16.4M | $-19.4M |
| EBITDA | $-17.4M | $-17.4M | $-16.0M | $-16.3M | $-19.3M |
| EPS | -0.38 | -0.38 | -0.51 | -0.83 | -0.98 |
| Balance Sheet | |||||
| Current Ratio | 8.04 | 8.04 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-21.6M | $-21.6M | $-23.5M | $-14.9M | $-8.6M |
| Returns | |||||
| ROE | -74.5% | -74.5% | -77.6% | -100.0% | -59.3% |
| Valuation | |||||
| P/B | 5.75 | 5.75 | 3.71 | 6.46 | 2.15 |
| Growth & Yield | |||||
| EPS Growth | 25.5% | 25.5% | 38.6% | 15.3% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-56.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.51 → -0.38
Residual
-56.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.